Eupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on Monday

Posted by ABMN Staff on Apr 5th, 2025

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) is projected to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Eupraxia Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ EPRX opened at $2.93 on Friday. The stock has a market cap of $104.41 million and a price-to-earnings ratio of -4.07. The business has a 50 day simple moving average of $3.54 and a 200 day simple moving average of $3.16. Eupraxia Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $4.48.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum started coverage on shares of Eupraxia Pharmaceuticals in a report on Friday, February 21st. They set a “buy” rating and a $12.00 price objective on the stock.

Get Our Latest Stock Analysis on EPRX

About Eupraxia Pharmaceuticals

(Get Free Report)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.